Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study.

Journal of autoimmunity - 1 Feb 2019

Di Scala Gerardo, Bettiol Alessandra, Cojan Rafaela Diana, Finocchi Martina, Silvestri Elena, Emmi Giacomo

Abstract excerpt

OBJECTIVE: To evaluate the efficacy and safety of secukinumab in Behçet's patients with active mucocutaneous and articular manifestations refractory to previous treatments. METHODS: We retrospectively evaluated 5 patients treated with the IL17-inhibitor secukinumab and diagnosed with Behçet according to ISG/ICBD criteria. All patients had active mucocutaneous and articular manifestations refractory to colchicine,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Behcet Syndrome

Share to Drug Resistance

Share to Interleukin-17

Share to Phenotype

Share to Retreatment

Share to Treatment Outcome

Source

Identifiers

PMID: 30213443
DOI: 10.1016/j.jaut.2018.09.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study.PMID 30213443Read ↗

Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study.Semantic proximity Read ↗

ANCA-associated vasculitis following secukinumab treatment for psoriasis: Expanding the Spectrum of IL-17A Inhibitor-Related Autoimmunity— A Case ReportSemantic proximity Read ↗

Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumabSemantic proximity Read ↗

Segmental stiff skin syndrome: a novel case with an interleukin-17C mutation successfully treated with secukinumab.Semantic proximity Read ↗

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.Semantic proximity Read ↗

Secukinumab Therapy for Netherton Syndrome.Semantic proximity Read ↗

Transcriptomic profiling of plaque psoriasis and cutaneous T cell subsets during treatment with secukinumabSemantic proximity Read ↗

Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy.Semantic proximity Read ↗

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex.Semantic proximity Read ↗

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.Semantic proximity Read ↗

Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab.Semantic proximity Read ↗

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.